Article Information
- Received August 27, 2023
- Revision received April 18, 2024
- Accepted April 21, 2024
- Published online July 1, 2024.
Author Information
- Alberto J. Espay1,
- Kasper P. Kepp2 and
- Karl Herrup3
- 1Department of Neurology, James J. and Joan A. Gardner Family Center for Parkinson’s Disease and Movement Disorders, University of Cincinnati, Cincinnati, Ohio 45219
- 2Section of Biophysical and Biomedicinal Chemistry, Department of Chemistry, Technical University of Denmark, Kongens Lyngby 2800, Denmark
- 3Department of Neurobiology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261
- Correspondence should be addressed to Karl Herrup at herrup{at}pitt.edu.
Author contributions
Author contributions: A.J.E., K.P.K., and K.H. wrote the paper.
Disclosures
The authors declare no competing financial interests.
Dr. A.J.E. has received grant support from the National Institutes of Health and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Neuroderm, Amneal Pharmaceuticals, Acadia, Avion Pharmaceuticals, Acorda Therapeutics, Kyowa Kirin, Sunovion, Supernus Pharmaceuticals (formerly, US WorldMeds), and Herantis Pharma; personal honoraria for speakership for Avion Pharmaceuticals, Amneal Pharmaceuticals, and Supernus Pharmaceuticals; and publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer. He cofounded REGAIN Therapeutics and is coinventor of the patent “Compositions and methods for treatment and/or prophylaxis of proteinopathies.” He serves on the editorial boards of the Journal of Parkinson's Disease, Journal of Alzheimer's Disease, European Journal of Neurology, Movement Disorders Clinical Practice, and JAMA Neurology. Drs. K.P.K. and K.H. have nothing to disclose.
Article usage
In this issue
